Tuesday 6th October 2020

(3 years, 6 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Helen Whately Portrait Helen Whately
- Hansard - - - Excerpts

The hon. Member makes an important point, as did my hon. Friend the Member for Derbyshire Dales (Miss Dines) a moment ago, about the importance of visiting for those in care homes, and for their relatives and loved ones. We are striking the difficult balance between protecting those in care homes and ensuring that they have visits wherever possible, but these visits must be done safely. I have heard from the sector about the aspiration for some family members to be treated as care workers—for instance, if they visit the care home regularly. As we expand testing, I very much intend that we should test some visitors—and am making the case for doing so—but it is all part of how we expand and use our testing resources.

Tonia Antoniazzi Portrait Tonia  Antoniazzi  (Gower) (Lab)
- Hansard - -

If he will make a statement on his departmental responsibilities.

Matt Hancock Portrait The Secretary of State for Health and Social Care (Matt Hancock)
- Hansard - - - Excerpts

On Friday we confirmed the 40 hospitals we will build by 2030 as part of a package worth £3.7 billion, with a further eight new schemes also invited to bid, all to ensure that we protect the NHS long into the future.

Tonia Antoniazzi Portrait Tonia Antoniazzi [V]
- Hansard - -

All I want from the Secretary of State today is a simple yes or no answer. It has come to light that the Northern Ireland authorities have taken unprecedented action and committed to pay for private prescriptions for medical cannabis for severely ill children. Will he do the right thing and follow the example set in Northern Ireland in supporting other children with intractable epilepsy by paying for their private prescriptions—yes or no?

Matt Hancock Portrait Matt Hancock
- Hansard - - - Excerpts

The hon. Lady has long been a campaigner on this subject. We have made significant progress in terms of expanding access where it is clinically safe to do so. On this, as on so many things, I will make sure that I constantly follow the clinical evidence.